In addition to the treatment of melanoma, IFN-α is approved for the treatment of some hematologic malignancies, AIDS-related Kaposi's sarcoma, and as a component in an anti-angiogenic combination regimen with bevacizumab for advanced renal cancer. Here, IFNA1 is linked to renal carcinoma.